Skip to main content

Day: June 22, 2020

Touchpoint Group Holdings Announces API for UPS® eFulfillment

MIAMI, Fla., June 22, 2020 (GLOBE NEWSWIRE) — Touchpoint Group Holdings, Inc. (OTCQB: TGHI) (Company or Touchpoint), a media and digital technology holding company, today announced that they have developed an application programming interface (API) for UPS eFulfillment on the Touchpoint app for iOS devices.The Touchpoint app platform provides subscribers the ability to view live stream content hosted by their favorite celebrities and elite influencers.  These celebrities may sponsor unique merchandise drops and sell exclusive merchandise through their Touchpoint apps.Through its API with UPS eFulfillment, Touchpoint can effectively, efficiently and reliably fulfill merchandise purchases made using celebrity influencer apps on the Touchpoint platform.  UPS has strategically placed UPS eFulfillment warehouses so that vendors can take...

Continue reading

Rafarma Inks Deal For CBD-Infused Drink Product

Ljubljana, Slovenia, June 22, 2020 (GLOBE NEWSWIRE) — Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce finalization of the agreement with Destination Marketing Group Co. Ltd. Thailand. Under the agreement, Destination Marketing will provide outsourcing services for production of CBD-infused natural Mango, Guava and Pineapple canned drinks for retail consumption. Destination marketing is already accepting bids from major producers in Thailand to produce the juices to be used with the Slovenian products developed by the Rafarma professional team. All of the ingredients for the products will be locally produced in Thailand. Initially the product will be packaged in 33 ml metal cans and will be marketed throughout Europe. The Company expects the wholesale price of the product to come between $0.25 and $0.28 per can. Rafarma...

Continue reading

Chicken Soup for the Soul Entertainment Announces Major Distribution Expansion for Crackle Plus on VOD and Linear Services

Initial Agreements Made with Plex, Xfinity Flex, and FuboTV With Plans to Add More   Company Launches Linear Services in Addition to VOD ServicesCOS COB, Conn., June 22, 2020 (GLOBE NEWSWIRE) — Chicken Soup for the Soul Entertainment Inc. (Nasdaq: CSSE), one of the largest operators of streaming advertising-supported video-on-demand (AVOD) networks, today announced major distribution expansion for Crackle Plus. The expansion will include  new services and devices as well as the first Crackle and Popcornflix linear channels.At today’s NewFronts presentation, Crackle Plus will announce that it has signed distribution deals with Plex, Xfinity Flex, and FuboTV this month and is targeting up to 10 total distribution partnerships for the year.“We are excited to continue to expand the devices and services on which consumers can watch our...

Continue reading

The Alkaline Water Company® Launches Direct to Consumer E-Commerce Website

Alkaline88.com E-commerce site complements our 70,000 stores strong retail presenceSCOTTSDALE, Ariz., June 22, 2020 (GLOBE NEWSWIRE) — The Alkaline Water Company Inc. (NASDAQ and CSE: WTER) (the “Company”), is a producer of premium bottled alkaline water, flavored-infused waters, and CBD infused products sold under the brand names Alkaline88®, A88 Infused™, and A88CBD™, respectively. The Company announced the launch of its new direct to consumer website Alkaline88.com, where consumers will be able to buy our full line of products, including Alkaline88® waters, A88 Infused favors™ and eco-friendly aluminum bottles.“We are proud to announce our new e-commerce website, Alkaline88.com. With the in-house expertise already in place from our e-commerce platform, A88CBD.com, which carries our hemp-derived CBD topical and...

Continue reading

APRU Announces second shipment of Element C to the Upper Midwest

TITUSVILLE, Fla., June 22, 2020 (GLOBE NEWSWIRE) — The Apple Rush Company, Inc. (US OTC PINK: APRU) (the “company”), a beverage maker, manufacturer of unique consumer brands and CBD and Kratom products and drinks, announced today that it has delivered the second order of Element C, CBD infused beverages to North Dakota.Apple Rush Company, Inc has delivered four additional pallets to our distributor in North Dakota.  This shipment was delivered Friday and deliveries to retailers will begin today. “It is exciting to see that progress has been made with Element C.  It has been well received and we are excited that it will be available in retailers now.  Our Midwest investors group has been very proactive in developing their market and we believe their success will create a model for distribution in more populous states.  CBD infused...

Continue reading

Adesto® Announces Completion of CFIUS Review for Proposed Acquisition of Adesto by Dialog Semiconductor

SANTA CLARA, Calif., June 22, 2020 (GLOBE NEWSWIRE) — Adesto Technologies Corporation (NASDAQ: IOTS), a leading provider of innovative application-specific semiconductors and embedded systems for the IoT, announces that in connection with the pending acquisition of Adesto by Dialog Semiconductor plc (XETRA:DLG), the parties have been informed by the Committee on Foreign Investment in the United States (CFIUS) that CFIUS has completed its review of the pending acquisition and determined that there are no unresolved national security concerns with respect to the proposed transaction. The parties expect the transaction to close on June 29, 2020, subject to customary closing conditions.About Adesto Technologies Corp.Adesto Technologies Corporation (NASDAQ:IOTS) is a leading provider of innovative application-specific semiconductors...

Continue reading

Champignon Announces Regulatory Review

VANCOUVER, British Columbia, June 22, 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) announces that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”).  The review relates to the Company’s disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding certain recent acquisitions completed by the Company.“With the recent growth and interest in our industry, ensuring our disclosure obligations are satisfied is at the forefront of our attention.  Ensuring fulsome and timely disclosure is vital to the success of our Company, and development of our industry with the investing public.  We look forward to working with staff of the British...

Continue reading

Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting

– Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells –– Translational data expand on scientific rationale for both ongoing EMERGE Phase 2 trial and upcoming SELECT trial –CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the presentation of new preclinical data from its JTX-1811 program and translational data from its ongoing vopratelimab program at the American Association for Cancer Research (AACR) Virtual Annual Meeting.“The progress we have made to date with both JTX-1811, our anti-CCR8 antibody,...

Continue reading

CytomX Therapeutics Announces Preclinical Data from Anti-CTLA-4 Probody Therapeutic Programs Presented by Partner Bristol Myers Squibb at AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that its partner Bristol Myers Squibb presented preclinical data from BMS-986249 and BMS-986288, anti-CTLA-4 Probody therapeutics generated with CytomX’s novel Probody® technology platform. The electronic poster #4551 titled “Preclinical characterization of novel anti-CTLA-4 prodrug antibodies with an enhanced therapeutic index” was presented as part of the Therapeutic Antibodies 3 Session at the American Association of Cancer Research’s (AACR) 2020 Virtual Annual Meeting II.BMS-986249 is a Probody version of the anti-CTLA-4 antibody ipilimumab (Yervoy®). In February 2020, Bristol Myers Squibb treated the first patient in a Part 2a randomized cohort expansion in an ongoing Phase 1/2a trial of BMS-986249 in combination...

Continue reading

iBrands Corporation Reports QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer

LAS VEGAS, June 22, 2020 (GLOBE NEWSWIRE) — iBrands Corporation  (OTC: IBRC) (“the Company”), a diversified holding and branding company, announces novel data suggesting that QuadraMune™ administration reduces the number and activity of immune inhibitory cells termed “myeloid suppressor cells.”In a series of animal studies using the triple-negative breast cancer 4T1 mouse model, the Company’s  nutraceutical manufacturer, Therapeutics Solutions International, Inc. (TSOI), described through its filed patent preliminary data suggest that administration of QuadraMune™ reduced lung metastasis on its own and increased efficacy of a “cancer vaccine”.  These data suggest that the nutraceutical, which is currently being tested as a preventative immune booster to protect against COVID-19[1], may have potential use...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.